返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Orthopedics Holds the Third TKA Training Course in Hong Kong

[2018-01-08] 

Hong Kong, China – Recently, MicroPort® Orthopedics hosted the third training course regarding total knee arthroplasty ("TKA") surgical technique in Queen Mary Hospital of the University of Hong Kong. A total of 13 knee replacement experts from Shanghai, Guangxi, Henan, Guizhou, Inner Mongolia, Jiangsu, Heilongjiang, Chongqing, Guangdong, Shandong and Hunan provinces attended the course to get a deeper understanding in the medial-pivot knee and exchange ideas on surgical techniques, blood management, pain management, and postoperative recovery.
 
The training course was chaired by Peter KY Chiu, a clinical professor and head of Ortho Recon of the Department of Orthopaedics & Traumatology of the University of Hong Kong, Queen Mary Hospital. As a renowned orthopedic expert, Professor Chiu is a life member of the Hong Kong Orthopaedic Association ("HKOA"). Professor Chiu has been engaged in providing medical education of knee surgical techniques to the Chinese mainland surgeons since 1998. From 2001, approximately 1,700 mainland orthopedic surgeons have come to Hong Kong for the surgical training.
 
This training course focused on how to apply TKA theories to practice. Professor Chun-Hoi Yan, Hon. Secretary of HKOA and Chairman of Adult Joint Recon of HKOA, introduced the design rationale of the medial-pivot knee and shared the key points of the medial pivot knee surgeries. He vividly illustrated the development of the medial pivot knee system, from the initial inspirations of natural knee clinical studies, the pros and cons of the traditional knee prosthesis, to the invention and application of the medial pivot knee. After learning about the medial-pivot knee theoretically, the trainees were divided into four groups for operation demonstrations. Professor Peter KY Chiu and Professor Chun-Hoi Yan explained to them key surgical skills from approach selection and soft tissue balance skills, to bone cut, alignment management, and sizer management.
 
As one of the well-known knee systems in the world, EVOLUTION® has gained high market recognition after it was launched in the US in 2010, later sold to Europe and Japan, and entered the Chinese mainland market and the Hong Kong market in 2015. According to a study evaluating long-term clinical and radiographic outcomes of the medial pivot knee system published in The Knee, the results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities.
 
This training course provided a thorough comprehension of the design rationale of the medial pivot knee as well as its advantages compared to traditional knee prostheses. Meanwhile, it is expected that the EVOLUTION™ surgical techniques the trainees learnt from the course would lay the foundation for them to carry out EVOLUTION™ surgeries in their local hospitals in the future. In 2018, MicroPort® Orthopedics will continue to work closely with Queen Mary Hospital of the University of Hong Kong to launch more TKA training courses, allowing more orthopedic surgeons to understand and use the medial pivot knee so as to benefit more patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® NeuroTech Attends CINS 2017
[Next]:MicroPort® Attends TCT to Display Firehawk® and Firesorb®